Literature DB >> 10763832

Ectopic pregnancy.

R Lehner1, E Kucera, S Jirecek, C Egarter, P Husslein.   

Abstract

Ectopic pregnancy is a implantation occurring elsewhere than in the cavity of the uterus, whereas ninety-nine percent of extrauterine pregnancies occur in the fallopian tube. The incidence of extrauterine pregnancy has increased from 0.5% thirty years ago, to a present day 1-2%. The most frequent cause of tubal pregnancy is previous salpingitis. Mortality rates for tubal pregnancies used to be approximately 1.7% in the 1970s but dropped to 0.3% in 1980s. DIAGNOSIS: Using transvaginal ultrasound it is possible to obtain positive evidence of an ectopic pregnancy at a very early stage. In cases of hCG titers>2,000 IU/l, intrauterine pregnancy can be diagnosed with certainty. The most important differential diagnosis of ectopic pregnancy is early intrauterine pregnancy. CLINICAL MANAGEMENT AND THERAPY: Regardless of the therapeutic strategy selected by the physician, informing the patient is a major aspect of the management of ectopic pregnancy. If surgery is considered appropriate, the patient must be informed about the nature, side effects and complications of the procedure. However, it should be remembered that in some cases, the actual chances of cure first become apparent at surgery. In asymptomatic patients with a serum hCG titer <1,000 IU/l that is falling, it is appropriate to wait and watch. In clinically stable patients with an unruptured tubal pregnancy and steady hCG levels, systemic treatment with methotrexate might also be considered. In unruptured tubal pregnancy with a hCG titer between 1,000 and 2,500, a further therapeutic alternative is intratubal injection of prostaglandins, hyperosmolar glucose of NaCl. Generally speaking, the currently widespread laparoscopic surgical treatment of the fallopian tube hardly influences the risk of recurrence. If the gestational mass is larger, the serum hCG titer higher than the approximate limit of 2,500 mU/ml and/or the tube already ruptured, surgery is usually required. PREVENTION: The most effective prevention is to avoid tubal inflammation or, in cases of preexisting inflammation, to administer effective therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10763832     DOI: 10.1007/s004040050001

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  7 in total

1.  Methotrexate treatment of ectopic pregnancy: experience at nizwa hospital with literature review.

Authors:  Hansa Dhar; Ilham Hamdi; Bhawna Rathi
Journal:  Oman Med J       Date:  2011-03

2.  Ultrasound in the Emergency Department Identifies Ectopic Pregnancy Post Hysterectomy: A Case Report.

Authors:  Allison Cohen; Dorothy Shi; Evan Keraney; Brendon Stankard; Mathew Nelson
Journal:  Clin Pract Cases Emerg Med       Date:  2022-05

3.  Assessment of early decline in the percentage of β-hCG values between days 0 and 4 after methotrexate therapy in ectopic pregnancy for the prediction of treatment success.

Authors:  Ebru Celik; Ilgın Türkçüoğlu; Abdullah Karaer; Pinar Kırıcı; Sevil Eraslan
Journal:  J Turk Ger Gynecol Assoc       Date:  2013-09-01

4.  Ectopic pregnancy treatment by combination therapy.

Authors:  Aneta Cymbaluk-Płoska; Anita Chudecka-Głaz; Sławomir Kuźniak; Janusz Menkiszak
Journal:  Open Med (Wars)       Date:  2016-12-16

5.  Transvaginal Ultrasound-Guided Methotrexate Instillation for Failed Medical Management of Ectopic Pregnancies in Subfertile Women.

Authors:  Nikita Naredi; Sumeet Ranjan Tripathy; Rajesh Sharma
Journal:  J Hum Reprod Sci       Date:  2022-03-31

6.  Neglected primary omental pregnancy after laparoscopic and medical treatment: a difficult diagnosis?

Authors:  Federica Martelli; Caterina De Carolis; Carmelo Parisi; Emilio Piccione
Journal:  Case Rep Obstet Gynecol       Date:  2013-06-02

7.  Laparoscopic management of tubal ectopic pregnancy.

Authors:  Dah-Ching Ding; Tang-Yuan Chu; Sheng-Po Kao; Pao-Chu Chen; Yu-Chi Wei
Journal:  JSLS       Date:  2008 Jul-Sep       Impact factor: 2.172

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.